The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Expression of Interferon Consensus Sequence Binding Protein (ICSBP) Is Downregulated in Bcr-Abl-Induced Murine Chronic Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP Inhibits Bcr-Abl-Induced Myeloproliferative Disorder
Open accessAbstract
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder resulting from the neoplastic transformation of a hematopoietic stem cell. The majority of cases of CML are associated with the (9;22) chromosome translocation that generates the bcr-abl chimeric gene. Alpha interferon (IFN-alpha) treatment induces hematological remission and prolongs life in 75% of CML patients in the chronic phase. It has been shown that mice deficient in interferon consensus sequence binding protein (ICSBP), a member of the interferon regulatory factor family, manifest a CML-like syndrome. We have shown that expression of Bcr-Abl in bone marrow (BM) cells from 5-fluorouracil (5-FU)-treated mice by retroviral transduction efficiently induces a myeloproliferative disease in mice resembling human CML. To directly test whether icsbp can function as a tumor suppressor gene, we examined the effect of ICSBP on Bcr-Abl-induced CML-like disease using this murine model for CML. We found that expression of the ICSBP protein was significantly decreased in Bcr-Abl-induced CML-like disease. Forced coexpression of ICSBP inhibited the Bcr-Abl-induced colony formation of BM cells from 5-FU-treated mice in vitro and Bcr-Abl-induced CML-like disease in vivo. Interestingly, coexpression of ICSBP and Bcr-Abl induced a transient B-lymphoproliferative disorder in the murine model of Bcr-Abl-induced CML-like disease. Overexpression of ICSBP consistently promotes rather than inhibits Bcr-Abl-induced B lymphoproliferation in a murine model where BM cells from non-5-FU-treated donors were used, indicating that ICSBP has a specific antitumor activity toward myeloid neoplasms. We also found that overexpression of ICSBP negatively regulated normal hematopoiesis. These data provide direct evidence that ICSBP can act as a tumor suppressor that regulates normal and neoplastic proliferation of hematopoietic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the mouse model with a CML-like disease induced by Bcr-Abl, ICSBP expression was also downregulated. Interestingly, the mouse disease was ameliorated by coexpression of ICSBP. (52)”
From Review: ICSBP/IRF-8: Its Regulatory Roles in the Development of Myeloid Cells (2002) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current Protocols in Immunology
(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,574
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,267
Daley, G. Q., Etten, R. A. V., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 2,141
Current protocols in immunology
Nezlin, R. S. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90114-d · Cited by 1,413
The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias
Epstein, F. H., Kurzrock, R., Gutterman, J. U., & Talpaz, M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810133191506 · Cited by 833
Pear, W. S., Miller, J. P., Xu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., Bronson, R. T., Aster, J. C., Scott, M. L., et al. (1998) · Blood · doi:10.1182/blood.v92.10.3780 · Cited by 761
Melo, J. (1996) · Blood · doi:10.1182/blood.v88.7.2375.bloodjournal8872375 · Cited by 728
Acute leukaemia in bcr/abl transgenic mice
Heisterkamp, N., Jenster, G. W., ten Hoeve, J., Zovich, D., Pattengale, P. K., & Groffen, J. (1990) · Nature · doi:10.1038/344251a0 · Cited by 660
Versatile retroviral vectors for potential use in gene therapy.
Hawley, R. G., Lieu, F. H., Fong, A. Z. C., & Hawley, T. S. (1994) · PubMed · Cited by 652
Holtschke, T., Löhler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., Lou, J., Knobeloch, K.-P., Gabriele, L., Waring, J. F., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81348-3 · Cited by 644
Flagged first, then by citations
Research works printed but not linked: 6
- Abelson H. T., 1970, Cancer Res., 30, 2213
- Hawley R. G., 1995, Gene Ther., 1, 136
- Kelliher M. A., 1993, Oncogene, 8, 1249
- 10.1128/MCB.13.1.588 · DOI · Paper page
- Pfeffer L. M., 1998, Cancer Res., 58, 2489
- Talpaz M., 1994, Semin. Oncol., 21, 3
Cited by
Sorted by citations
Items 101–143 of 143
Thioredoxin reductase plays a critical role in IFN retinoid-mediated tumor-growth control in vivo.
Lindner, D. J., Ma, X., Hu, J., Karra, S., & Kalvakolanu, D. V. (2002) · PubMed · Cited by 14
Positive histone marks are associated with active transcription from a methylated ICSBP/IRF8 gene
Tshuikina, M., Nilsson, K., & Oberg, F. G. (2008) · Gene · doi:10.1016/j.gene.2007.12.013 · Cited by 12
IRF-4 Suppresses BCR/ABL Transformation of Myeloid Cells in a DNA Binding-independent Manner
Jo, S., & Ren, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.289728 · Cited by 11
Self-citationHuang, W., Bei, L., Hjort, E. E., & Eklund, E. A. (2017) · Oncotarget · doi:10.18632/oncotarget.16884 · Cited by 11
Immunotherapeutic approaches in chronic myelogenous leukemia
Guilhot, F., Roy, L., Saulnier, P., Guilhot, J., Barra, A., Gombert, J., & Turhan, A. G. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190801927510 · Cited by 11
Hara, T., Schwieger, M., Kazama, R., Okamoto, S., Minehata, K., Ziegler, M., Löhler, J., & Stocking, C. (2008) · Oncogene · doi:10.1038/sj.onc.1211043 · Cited by 10
Pérez-Caro, M., & Sánchez-Garcı́a, I. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-200-7_1 · Cited by 9
Shah, C. A., Broglie, L., Hu, L., Bei, L., Huang, W., Dressler, D. B., & Eklund, E. A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000528 · Cited by 9
Huang, W., Liu, B., & Eklund, E. A. (2020) · Leukemia · doi:10.1038/s41375-020-0771-7 · Cited by 9
Huang, W., Hu, L., Bei, L., Hjort, E. E., & Eklund, E. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.294884 · Cited by 9
Immunotherapy in Chronic Myelogenous Leukemia
Guilhot, F., Roy, L., Martineau, G., Guilhot, J., & Millot, F. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.004 · Cited by 9
Ma, S. L., Sørensen, A. B., Kunder, S., Sørensen, K. D., Quintanilla‐Martínez, L., Morris, D. W., Schmidt, J., & Pedersen, F. S. (2006) · Virology · doi:10.1016/j.virol.2006.05.006 · Cited by 8
Jahn, T., Seipel, P., Coutinho, S., Miething, C., Peschel, C., & Duyster, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107030200 · Cited by 8
Huang, X., Ma, T., Zhu, Y., Jiao, B., Yu, S., Wang, K., Mi, J., & Ren, R. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0858-1 · Cited by 7
Self-citationDissecting the Molecular Mechanism of Chronic Myelogenous Leukemia Using Murine Models
Ren, R. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819021000002875 · Cited by 6
Self-citationInterferon regulatory factor 5 in Rheumatoid arthritis and systemic lupus erythematosus
Ebrahimiyan, H., Bagheri‐Hosseinabadi, Z., & Abbasifard, M. (2021) · Rheumatology Research · doi:10.22631/rr.2021.69997.1110 · Cited by 5
BCR-ABL as a target for novel therapeutic interventions
Kindler, T., Meyer, R., & Fischer, T. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.1.85 · Cited by 4
The Maintaining and Directed Differentiation of Hematopoietic Stem Cells Under Microgravity
Wang, P., Qian, J., Tian, H., & Zhao, Y. X. (2019) · Research for development · doi:10.1007/978-981-13-6325-2_9 · Cited by 4
Williams, O., Hu, L., Huang, W., Patel, P. A., Bartom, E. T., Bei, L., Hjort, E. E., Hijiya, C., & Eklund, E. A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104867 · Cited by 3
Molecular Biology and Cytogenetics of Chronic Myeloid Leukemia
Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_4 · Cited by 3
Role of Lipoxygenases in Pathogenesis of Cancer
Roos, J., Kuhn, B. R., Fettel, J., Maucher, I. V., Ruthardt, M., Kahnt, A. S., Vorup‐Jensen, T., Matrone, C., Steinhilber, D., & Maier, T. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-27766-0_7 · Cited by 3
Molecular Biology and Cytogenetics of Chronic Myeloid Leukemia
Konopleva, M. Y., Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_4 · Cited by 3
Shires, K., Shankland, I., Mowla, S., Njikan, S., & Jaymacker, J. (2014) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2014.01.001 · Cited by 2
The Interferon Alpha Revival in CML
Talpaz, M., Mercer, J., & Hehlmann, R. (2016) · Hematologic malignancies · doi:10.1007/978-3-319-33198-0_14 · Cited by 2
Bcr-Abl and Signal Transduction
Cilloni, D., & Saglio, G. N. (2007) · Springer eBooks · doi:10.1007/978-3-540-34506-0_2 · Cited by 1
Ikushima, H., Yanai, H., & Taniguchi, T. (2015) · Springer eBooks · doi:10.1007/978-4-431-55327-4_7 · Cited by 1
Novel prognostic factors in chronic myeloid leukemia
Lundán, T. (2008) · Työväentutkimus Vuosikirja · Cited by 1
Mechanisms of Transcriptional Regulation
Marecki, S., & Fenton, M. J. (2000) · Cited by 2
Etten, R. A. V. (2008) · Springer eBooks · doi:10.1007/978-0-387-69132-9_1
Esposito, N. (2008) · Università degli Studi di Napoli Federico II · doi:10.6092/unina/fedoa/3382
Novel Therapeutic Targets for Ph+ Chromosome Leukemia and Its Leukemia Stem Cells: A Dissertation
Peng, C. (2010) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/c6dc-6x97
Pitha, P. M., & Alce, T. M. (2002) · Wiley Encyclopedia of Molecular Medicine · doi:10.1002/0471203076.emm0446
WILMS’ TUMOUR GENE 1 PROTEIN (WT1) – AN EFFECTOR IN LEUKEMOGENESIS?
Vidovic, K. (2010) · Lund University Publications (Lund University)
Overriding BCR/ABL mitotic signal by ICSBP-induced differentiation
Ren, R. (2003) · Blood · doi:10.1182/blood-2003-10-3376
Self-citationVidovic, K. (2010)
Nardi, V., Naveiras, O., Azam, M., & Daley, G. Q. (2014)
Cytogenetics and molecular biology of chronic myeloid leukemia
Deininger, M. W. (2013) · CRC Press eBooks · doi:10.3109/9780203091616-6
Oncogenic Forms of ABL Family Kinases
Ren, R. (2008) · Springer eBooks · doi:10.1007/978-0-387-68744-5_7
Self-citationThe Interferon-Alpha Revival in CML
Talpaz, M., Mercer, J., & Hehlmann, R. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-71913-5_13
C ytogenetics and molecular biology of chronic myeloid leukemia
Rosée, P. G. L., & Deininger, M. W. (2008) · CRC Press eBooks · doi:10.3109/9780203091616-3
Cozzi, E., Neddermeyer, A., Miliara, S., Zhong, X., Weirick, T., Struyf, N., Erkers, T., Hon, C. C., Lennartsson, A., & Lehmann, S. (2026) · Non-coding RNA Research · doi:10.1016/j.ncrna.2026.05.002
NEGATIVE REGULATION OF REGULATORY T CELLS BY MYELOID-DERIVED SUPPRESSOR CELLS IN CANCER
Centuori, S. M. (2011) · UA Campus Repository (The University of Arizona)
Metadata
- Authors
- Hao, S. X., & Ren, R.
- Affiliations
- Brandeis University (US)
- ORCID
- Ren, Ruibao
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2000-02-01
- Volume
- 20
- Issue
- 4
- Pages
- 1149-1161
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC85233
- OpenAlex
- W2096038076
- Cited by
- 143
- References
- 48
- Citations by year
- 2026: 1 · 2023: 1 · 2021: 5 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 10 · 2015: 6 · 2014: 4 · 2013: 5 · 2012: 6
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular and Cellular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA68008, R01CA068008)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- IRF8, BCR-ABL, chronic myeloid leukemia, myeloproliferative neoplasms, tumor suppressor, interferon regulatory factors, B-cell lymphoproliferative disorders, hematopoietic regulation, bone marrow cells, retroviral transduction, colony formation
- MeSH terms
- Interferon Regulatory Factor-8, Animals, Antimetabolites, Antineoplastic, B-Lymphocytes, Base Sequence, Colony-Forming Units Assay, Disease Models, Animal, Fluorouracil, Hematopoiesis, Humans, Interferons, Lymphoproliferative Disorders, Male, Mice, Inbred BALB C, Myeloproliferative Disorders, Repressor Proteins, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Down-Regulation, Bone Marrow Transplantation, Genes, abl, Consensus Sequence, DNA Primers, Interferon Regulatory Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
